Immunotherapy of malignant melanoma – Basic principles and novel therapeutic approaches
- 1 August 2006
- journal article
- abstracts
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 4 (8) , 635-644
- https://doi.org/10.1111/j.1610-0387.2006.06033.x
Abstract
Immunotherapy has assumed increasing importance in the therapy of malignant melanoma. The main reason is the high immunogenicity of the tumor itself, so that an immune response against the tumor often exists even without immune stimulation. The goal of modern immunotherapeutic approaches is to augment these anti-tumoral immune reactions to fight the tumor. Despite multiple successes, the ultimate breakthrough in the therapy of malignant melanoma has not yet been achieved. This overview summarizes the reasons for this lack of success and highlights future strategies for more successful therapy of malignant melanoma.Keywords
This publication has 53 references indexed in Scilit:
- Induction of strong and persistent MelanA/MART‐1‐specific immune responses by adjuvant dendritic cell‐based vaccination of stage II melanoma patientsInternational Journal of Cancer, 2006
- Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T CellsJournal of Clinical Oncology, 2005
- Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cellsThe Journal of Experimental Medicine, 2005
- Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanomaInternational Journal of Cancer, 2005
- Mini‐review: Overcoming tumor‐intrinsic resistance to immune effector functionEuropean Journal of Immunology, 2004
- Virotherapeutics: conditionally replicative adenoviruses for viral oncolysisAnti-Cancer Drugs, 2003
- Differential Expression of Inhibitory or Activating CD94/NKG2 Subtypes on MART-1-Reactive T Cells in Vitiligo Versus Melanoma: A Case ReportJournal of Investigative Dermatology, 2002
- A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injectionInternational Journal of Cancer, 2001
- Expression of CD94/NKG2 Subtypes on Tumor-Infiltrating Lymphocytes in Primary and Metastatic MelanomaJournal of Investigative Dermatology, 2000
- Predominant Expression of Fas (CD95) Ligand in Metastatic Melanoma Revealed by Longitudinal AnalysisJournal of Investigative Dermatology, 1999